In complete agreement with our findings in ERRα-null mice, a report published during preparation of this manuscript showed that administration of a novel highly selective ERRα inverse agonist (compound 29) in diet-induced murine models of obesity and an overt diabetic rat model resulted in improved insulin sensitivity and glucose tolerance accompanied by reduced circulating glucose, free fatty acid and triglyceride levels [48]. The gene discussed is ESRRA; the disease is obesity disorder.